Nicole Iida - MEI Pharma Vice Affairs

MEIP Stock  USD 2.43  0.03  1.22%   

Executive

Nicole Iida is Vice Affairs of MEI Pharma
Address 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121
Phone858 369 7100
Webhttps://meipharma.com

MEI Pharma Management Efficiency

The company has return on total asset (ROA) of (0.3068) % which means that it has lost $0.3068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9368) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/05/2025, Return On Tangible Assets is likely to grow to 0.41. Also, Return On Capital Employed is likely to grow to 0.42. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/05/2025, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.
MEI Pharma currently holds 8.36 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. MEI Pharma has a current ratio of 6.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about MEI Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Debra SieminskiTerns Pharmaceuticals
N/A
Verender BadialZura Bio Limited
53
Philip EsqOcular Therapeutix
64
Lauren MBADay One Biopharmaceuticals
49
YuWaye MDCytomX Therapeutics
57
Pattie ChiangKezar Life Sciences
N/A
Danielle OlanderMoghadassianCytomX Therapeutics
N/A
KarenLeigh MBAOcular Therapeutix
N/A
JD EsqTerns Pharmaceuticals
56
Sandra VedrickRevelation Biosciences
N/A
Melita JungTerns Pharmaceuticals
48
Shannon RyanAssembly Biosciences
N/A
Shree PatelAchilles Therapeutics PLC
N/A
Andrew GengosTerns Pharmaceuticals
61
Alan FreidmanTranscode Therapeutics
N/A
Adam DubowDay One Biopharmaceuticals
57
Edward SamuelAchilles Therapeutics PLC
N/A
Steve MeyersOcular Therapeutix
N/A
Tracy SmithOcular Therapeutix
N/A
Amy CFAAssembly Biosciences
N/A
Mark SchillerKezar Life Sciences
45
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. MEI Pharma (MEIP) is traded on NASDAQ Exchange in USA. It is located in 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121 and employs 28 people. MEI Pharma is listed under Biotechnology category by Fama And French industry classification.

Management Performance

MEI Pharma Leadership Team

Elected by the shareholders, the MEI Pharma's board of directors comprises two types of representatives: MEI Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MEI. The board's role is to monitor MEI Pharma's management team and ensure that shareholders' interests are well served. MEI Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MEI Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Justin CPA, CFO CEO
BA Esq, COO Counsel
Anne Frese, Chief Officer
Eugene Park, VP Marketing
Virginia Sankey, VP Fin
JD Esq, Chief Officer
Eric Deng, VP Operations
Richard Ghalie, Chief Officer
MBA MD, Chief Officer
LLM JD, Senior Affairs
Robert Mass, Chief Medical Officer
BA CPA, CFO Sec
Justin File, CFO Secretary
Nicole Iida, Vice Affairs
Daniel Gold, CEO and President and Director
Yomara GomezNaiden, Senior Quality

MEI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MEI Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.